Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 Supplement for Long COVID in Health Care Workers
NCT05121766Phase 1Terminated
- Sponsor
- Hackensack Meridian Health
- Start
- Jan 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of eicosapentaenoic acid + docosahexaenoic acid in post acute COVID-19 syndrome (2 arms), sponsored by Hackensack Meridian Health. Primary endpoints: Feasibility Study for Omega-3 Fatty Acid Supplementation v. Placebo in Adult Patients to Limit Long Covid Syndrome - Compliance at 12 weeks, Feasibility Study for Omega-3 Fatty Acid Supplementation v. Placebo in Adult Patients to Limit Long Covid Syndrome - Recruitment at 6 months and 1 more. Started Jan 2022; status: terminated.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT05121766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05121766.